Employee Engagement Innovator Workplace Options Launches Executive Coaching Program to Elevate Human-Centered Leadership and Enhance Business Outcomes
Globe Newswire11-07-2024, 18:30
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia 21-09-2024, 15:15
